Getmyboat Helps Boat Businesses Grow with a Powerful Direct Booking Feature

The world’s leading boat rental platform launches a new solution for charter businesses to streamline payments and scheduling for just 1.5%

Getmyboat Launches Direct Booking Feature

The world’s leading boat rental platform launches a new solution for charter businesses to streamline payments and scheduling for just 1.5%

MENLO PARK, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) — Getmyboat, the world’s leading booking platform for yacht charters and boat rentals, is thrilled to announce the launch of its Direct Booking feature.

While consulting with partners of boating businesses of all sizes, Getmyboat discovered that many owners shared struggles in managing bookings from off-platform sources, including payment processing issues like fraud and chargebacks, claims management, fees for accepting credit payments, scheduling, renter communication and more which led to organizational headaches. To remedy these challenges, Getmyboat is focused on building a comprehensive software solution specifically designed for boat rental, yacht charter, and boat tour companies, and is constantly introducing new ways for owners to manage their entire business. The launch of Direct Booking on the Getmyboat app is a major first step in streamlining booking management, all for just 1.5%, which is among the lowest rates in the industry. Whether through their own websites, by email, Facebook, phone calls, or in person – Getmyboat owners can now take all leads and seamlessly turn them into bookings making it easier for them and their customers.

Key Benefits of Getmyboat’s Direct Booking

Unified Management: Boat owners can now consolidate all bookings, regardless of the source, into one comprehensive platform, eliminating the need for multiple software solutions and calendars.

Simplified Offers and Payment Processing: With a few simple steps, owners can send out offers, securely collect payments including credit cards, and automatically synchronize bookings with their overall calendar, ensuring a hassle-free transaction process for both the owner and renter.

Fraud Protection and Dispute Resolution: Direct Booking benefits from Getmyboat’s robust software, providing owners with fraud protection, claims process management, and efficient dispute resolution for all transactions.

Low Cost: Boating businesses only pay 1.5% per transaction to use the service. Not only does this cover credit card fees, but includes all the other integration features above.

Frank D, a fleet owner in Miami, expressed his enthusiasm, stating, “I’m really excited to use this new feature. Now, I will be able to see everything in one place, communicate with my clients on a single platform, and collect payments simply. And I’ll know where all my boats are supposed to be no matter where the customer came from originally.”

Bryan Petro, Getmyboat President, shared “We’re thrilled to bring Direct Booking to our partners. We know they have a tremendously hard job on the logistics side of the business, and we can take what we’ve built and extend it to everyone to help their businesses grow.”

Getmyboat owners can easily get started by opening the app or website, navigating to their inbox, and clicking on the “Add a Direct Booking” option. From there, they can enter customer and trip information, streamlining their management processes directly within their Getmyboat account.

As the top source of customers for boating businesses globally, Getmyboat continues to innovate to address the challenges faced by owners in managing their business across various platforms and is on a mission to provide the best growth tools in the industry.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d68cd4be-e68b-45b8-8caa-b31733c18679

For further information, please contact:

Val Streif
Getmyboat
[email protected]
+1 612-298-2535

GlobeNewswire Distribution ID 8994552

Getmyboat Helps Boat Businesses Grow with a Powerful Direct Booking Feature

The world’s leading boat rental platform launches a new solution for charter businesses to streamline payments and scheduling for just 1.5%

Getmyboat Launches Direct Booking Feature

The world’s leading boat rental platform launches a new solution for charter businesses to streamline payments and scheduling for just 1.5%

MENLO PARK, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) — Getmyboat, the world’s leading booking platform for yacht charters and boat rentals, is thrilled to announce the launch of its Direct Booking feature.

While consulting with partners of boating businesses of all sizes, Getmyboat discovered that many owners shared struggles in managing bookings from off-platform sources, including payment processing issues like fraud and chargebacks, claims management, fees for accepting credit payments, scheduling, renter communication and more which led to organizational headaches. To remedy these challenges, Getmyboat is focused on building a comprehensive software solution specifically designed for boat rental, yacht charter, and boat tour companies, and is constantly introducing new ways for owners to manage their entire business. The launch of Direct Booking on the Getmyboat app is a major first step in streamlining booking management, all for just 1.5%, which is among the lowest rates in the industry. Whether through their own websites, by email, Facebook, phone calls, or in person – Getmyboat owners can now take all leads and seamlessly turn them into bookings making it easier for them and their customers.

Key Benefits of Getmyboat’s Direct Booking

Unified Management: Boat owners can now consolidate all bookings, regardless of the source, into one comprehensive platform, eliminating the need for multiple software solutions and calendars.

Simplified Offers and Payment Processing: With a few simple steps, owners can send out offers, securely collect payments including credit cards, and automatically synchronize bookings with their overall calendar, ensuring a hassle-free transaction process for both the owner and renter.

Fraud Protection and Dispute Resolution: Direct Booking benefits from Getmyboat’s robust software, providing owners with fraud protection, claims process management, and efficient dispute resolution for all transactions.

Low Cost: Boating businesses only pay 1.5% per transaction to use the service. Not only does this cover credit card fees, but includes all the other integration features above.

Frank D, a fleet owner in Miami, expressed his enthusiasm, stating, “I’m really excited to use this new feature. Now, I will be able to see everything in one place, communicate with my clients on a single platform, and collect payments simply. And I’ll know where all my boats are supposed to be no matter where the customer came from originally.”

Bryan Petro, Getmyboat President, shared “We’re thrilled to bring Direct Booking to our partners. We know they have a tremendously hard job on the logistics side of the business, and we can take what we’ve built and extend it to everyone to help their businesses grow.”

Getmyboat owners can easily get started by opening the app or website, navigating to their inbox, and clicking on the “Add a Direct Booking” option. From there, they can enter customer and trip information, streamlining their management processes directly within their Getmyboat account.

As the top source of customers for boating businesses globally, Getmyboat continues to innovate to address the challenges faced by owners in managing their business across various platforms and is on a mission to provide the best growth tools in the industry.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d68cd4be-e68b-45b8-8caa-b31733c18679

For further information, please contact:

Val Streif
Getmyboat
[email protected]
+1 612-298-2535

GlobeNewswire Distribution ID 8994552

Un nouveau comité consultatif de centre pour Fortrea

Ce comité consultatif rassemble des leaders de la recherche autour de l’évolution des relations entre les centres, les promoteurs et les patients

DURHAM, État de Caroline du Nord, 14 déc. 2023 (GLOBE NEWSWIRE) — Fortrea (Nasdaq : FTRE), ci-après la « Société », une organisation mondiale de recherche contractuelle de premier plan (ou CRO, de l’anglais Contract Research Organization), annonce ce jour que la première réunion de son comité consultatif de centre s’est tenue la semaine dernière. L’ordre du jour visait la collaboration entre les centres de recherche clinique, ci-après « les centres » et les leaders de l’industrie dans le but de créer une expérience améliorée en matière d’essai clinique au bénéfice des centres, des patients et des promoteurs d’études, ci-après « les promoteurs », ciblés sur les évolutions technologiques, la planification opérationnelle et la prestation, les modalités commerciales et l’engagement communautaire.

Fortrea place les centres et les investigateurs au cœur de la planification des essais cliniques, exploitant leurs perspectives pour amener des changements orientés vers l’accélération des essais, la simplification du démarrage des études, mais aussi l’optimisation du recrutement. Ces évolutions constituent une réponse aux enjeux des essais cliniques, posés de longue date, et induiront une meilleure expérience pour les centres, les patients et les promoteurs. Le comité consultatif de centre sera chargé d’apporter des éclairages et des commentaires en lien avec les stratégies et les solutions proposées pour les centres, les patients, les essais et la technologie applicable.

« Centres et investigateurs sont essentiels à chaque étape du développement clinique ; ils font habituellement face à des enjeux complexes rien qu’en matière d’essais cliniques. Nous recueillons favorablement leurs avis lors de la conception des protocoles, et les faisons activement participer aux premiers débats entre nos équipes opérationnelles et nos promoteurs pour déterminer rapidement la planification d’essais cliniques les plus efficaces et les mieux axés sur les patients » observe Mike Clay, Vice-président de la stratégie de développement et de croissance chez Fortrea. Et de poursuivre : « La formation du comité consultatif de centre marque l’accélération de notre stratégie envers les centres, et rassemble autour de la table un groupe de réflexion sur notre industrie, composé d’éminents leaders. Ce comité sera le pilier de notre aptitude à répondre aux promoteurs avec des concepts orientés vers la prévisibilité de leurs essais. Nous travaillerons ensemble à l’élaboration de calendriers d’essais pertinents, et nous renforcerons leur confiance en accélérant à la fois le processus de recrutement des patients et la conclusion globale des essais ».

Les premiers membres du comité consultatif de centre de Fortrea comptent des leaders et des experts de Circuit Clinical, Elligo Health Research, FutureMeds, Javara, ObjectiveHealth, Pratia S.A., Velocity Clinical Research, et de la fondation espagnole et centre de recherche contre le cancer MD Anderson Cancer Center, soit 440 centres spécialisés dans plus de 25 domaines thérapeutiques, originaires de neuf pays, élargissant ainsi l’accès à toute une diversité de communautés de patients.

Opinions exprimées par les membres du comité consultatif de centre de Fortrea :

Selon Łukasz Bęczkowski, Directeur des opérations chez Pratia, « Cette approche collaborative, réunissant à la fois les CRO et les centres, permettra un meilleur alignement de tous les acteurs de la recherche clinique envers les perspectives du marché des essais cliniques, et nous donnera incontestablement une meilleure force de frappe. De telles initiatives sont capitales pour induire de rapides évolutions positives ».

Nick Spittal, Directeur des opérations de Velocity Clinical Research, estime que « Fortrea a opté pour une approche privilégiant l’écoute en conférant aux centres la possibilité de s’exprimer légitimement sur les meilleures pratiques de travail pour dynamiser à la fois les communautés de patients et les acteurs concernés de ces centres. Il en résulte un meilleur service pour les promoteurs des essais cliniques ».

D’après Barry Simms, Directeur des opérations d’Elligo Health Research, « Fortrea se place à la pointe de l’industrie en améliorant la productivité et l’efficacité des partenariats du processus d’essai jusqu’aux relations commerciales, tout en s’efforçant d’accélérer la mise en marché de nouveaux produits ».

Pour la Directrice générale d’ObjectiveHealth, Colleen Hoke, « Fournir une solution d’accès aux patients appropriée est indispensable au succès d’un essai clinique. Les prestataires de soins de santé n’ont jusqu’ici pas été impliqués dans les premiers débats visant la planification et la stratégie de recherche ». Radek Janiak, Directeur général de FutureMeds, déclare « Saluer l’approche innovante de Fortrea, axée sur l’échange avec les organisateurs de partenariats des établissements de santé, essentiels à la réussite précoce des résultats de recherche dans le processus de planification.

FutureMeds se réjouit de rejoindre le comité consultatif de centre de Fortrea pour contribuer à la meilleure compréhension entre les acteurs clés de la recherche clinique ». Enfin, pour Michelle Rule, Vice-présidente en chef de l’optimisation professionnelle chez Javara, « Entendre la voix des patients, des investigateurs et des centres placera Fortrea en pole position pour introduire de nouveaux traitements sur le marché.

Naviguer le gigantesque écosystème des essais cliniques est complexe et nécessite des partenariats très fonctionnels, centrés sur la confiance et la compétence. Fortrea s’engage véritablement en faveur du dialogue et des relations de travail à travers son comité consultatif de centre, qui témoigne de son dévouement envers le progrès visant toutes les parties prenantes de la recherche, et surtout les patients ».

À propos de Fortrea

Fortrea (Nasdaq : FTRE) figure parmi les principaux fournisseurs de solutions de développement clinique et d’accès aux soins pour les patients dans le secteur mondial des sciences de la vie. Fortrea s’associe à des sociétés établies et émergentes du domaine biopharmaceutique, des dispositifs médicaux et des diagnostics pour stimuler l’innovation en matière de santé, et accélérer la mise au point de traitements révolutionnaires pour les patients qui en ont besoin. Nous proposons des services de gestion d’essais cliniques de phase I à IV, de pharmacologie clinique, d’essais différenciés axés sur des technologies habilitantes, et des services post-autorisation. Nos solutions s’appuient sur 30 ans d’expérience dans 20 domaines thérapeutiques, une passion pour la rigueur scientifique, des connaissances exceptionnelles et un solide réseau de centres de recherche. Notre équipe talentueuse et diversifiée d’environ 19 000 collaborateurs répartis sur plus de 90 pays est dimensionnée pour fournir des solutions ciblées et agiles à nos clients, partout dans le monde. Pour en savoir plus sur la manière dont Fortrea est moteur d’influence du pipeline au patient, rendez-vous sur Fortrea.com et suivez-nous sur LinkedIn et X (anciennement Twitter) @Fortrea.

Coordonnées de Fortrea :
Relations médias auprès de Fortrea : Galen Wilson – 703-298-0802, media@fortrea.com
Médias : Kate Dillon – 646-818-9115, kdillon@prosek.com

GlobeNewswire Distribution ID 8994772

Fortrea Convoca Novo Conselho Consultivo de Locais

Conselho Consultivo de Locais da Fortrea reúne líderes de pesquisa focados na evolução das relações com os locais, patrocinadores e pacientes

DURHAM, N.C., Dec. 14, 2023 (GLOBE NEWSWIRE) — A Fortrea (Nasdaq: FTRE) (a “Empresa”), uma organização líder global de pesquisa por contrato (CRO), anunciou hoje que convocou na semana passada a reunião inaugural do seu Conselho Consultivo de Locais, uma colaboração entre locais de pesquisa clínica (“locais”) e líderes da indústria para criar uma melhor experiência de ensaio clínico para locais, pacientes e patrocinadores de estudos clínicos (“patrocinadores”), visando mudanças na tecnologia, planejamento e entrega operacional, termos comerciais e envolvimento da comunidade.

A Fortrea coloca as unidades e os investigadores na vanguarda do planejamento de ensaios clínicos, utilizando suas perspectivas para impulsionar mudanças para o aprimoramento da velocidade da execução do ensaio, facilidade do início do estudo e aumento da eficiência do recrutamento. Essas mudanças abordam desafios de longa data para os ensaios clínicos e resultarão em uma melhor experiência do estudo no local, no paciente e no patrocinador. O Conselho Consultivo de Locais será responsável por fornecer informações e feedback sobre estratégias e soluções propostas em relação aos locais, pacientes, operações de teste e tecnologia relevante.

“Os locais e os pesquisadores são fundamentais para a indústria em todas as fases do desenvolvimento clínico, e tradicionalmente enfrentam desafios difíceis de resolver apenas em ensaios clínicos. Damos as boas-vindas aos seus insights sobre o design do protocolo e os convidamos a participarem ativamente das conversas iniciais com nossas equipes operacionais e patrocinadores para o rápido estabelecimento dos planos de estudo mais eficientes e focados no paciente”, disse Mike Clay, vice-presidente de Estratégia de Desenvolvimento e Crescimento da Fortrea. “A formação do Conselho Consultivo de Locais acelera a nossa estratégia focada nos Locais e inclui a representação de líderes incrivelmente impressionantes, criando um think tank para a nossa indústria. O Conselho também servirá como uma pedra angular para a nossa capacidade de responder aos patrocinadores com insights que melhorem a previsibilidade dos seus ensaios, trabalhando juntos para desenvolver planos operacionais eficientes e fornecer aos patrocinadores um alto grau de confiança na velocidade do recrutamento de pacientes e na entrega geral do ensaio.”

Os membros inaugurais do Conselho Consultivo de Locais da Fortrea incluem líderes e especialistas da Circuit Clinical, Elligo Health Research, FutureMeds, Javara, MD Anderson Cancer Center Foundation Spain, ObjectiveHealth, Pratia S.A. e Velocity Clinical Research, representando 440 locais em mais de 25 áreas terapêuticas e nove países, e fornecendo acesso a diversas comunidades de pacientes.

O que os membros do Conselho Consultivo de Locais da Fortrea estão dizendo…

“Acreditamos firmemente que essa abordagem colaborativa, reunindo o CRO e as unidades, permitirá que todas as partes interessadas se alinhem de forma mais eficaz às perspectivas do mercado de ensaios clínicos”, disse Łukasz Bęczkowski, diretor de operações da Pratia. “Isso, sem dúvida, nos capacita a agir juntos de maneira mais eficiente. Iniciativas como essas são essenciais para impulsionar todos nós em direção a mudanças positivas e rápidas.”

“A Fortrea está adotando uma abordagem de “ouvir primeiro”, dando aos locais uma voz igual para as práticas de trabalho mais eficazes para comunidades dinâmicas de pacientes e partes interessadas no local, resultando em um melhor serviço para os patrocinadores de ensaios clínicos”, disse Nick Spittal, diretor de operações da Velocity Clinical Research.

“A Fortrea está liderando o setor para tornar as parcerias mais produtivas e eficientes, desde o processo de teste até as relações comerciais, tudo no esforço de acelerar o lançamento de novos produtos no mercado”, disse Barry Simms, diretor de operações da Elligo Health Research.

“Uma solução de acesso ao paciente apropriada é essencial para determinar o sucesso final de um ensaio clínico. Historicamente, os prestadores de cuidados não participam do desenvolvimento inicial do planejamento e da estratégia da pesquisa”, disse Colleen Hoke, diretora executiva da ObjectiveHealth. “Apoiamos muito a Fortrea no emprego de uma nova abordagem inovadora para envolvimento com os provedores de parcerias de locais de saúde, que são fundamentais para a obtenção de resultados de pesquisa bem-sucedidos, desde o início do processo de planejamento.”

“A FutureMeds tem o prazer de fazer parte do Conselho Consultivo de Locais da Fortrea para criar um melhor entendimento entre as principais partes interessadas no setor de pesquisa clínica”, disse Radek Janiak, diretor executivo da FutureMeds. “Ao ouvir os pacientes, pesquisadores e locais a Fortrea passa a ter uma posição de destaque para a oferta de novas terapias no mercado.”

“O trabalho com o vasto ecossistema de ensaios clínicos é complexo e requer parcerias altamente funcionais centradas na confiança e na competência”, disse Michelle Rule, vice-presidente sênior de otimização empresarial da Javara. “O compromisso genuíno da Fortrea com a criação de um fórum e relações de trabalho por meio do Conselho Consultivo de Locais é um exemplo da dedicação ao progresso de todas as partes interessadas na pesquisa e, acima de tudo, dos pacientes.”

Sobre a Fortrea

A Fortrea (Nasdaq: FTRE) é fornecedora líder global de soluções para o desenvolvimento clínico e acesso ao paciente para a indústria de ciências da vida. Fazemos parcerias com grandes e emergentes empresas biofarmacêuticas, de dispositivos médicos e de diagnóstico para impulsionar a inovação na saúde que acelera terapias que mudam a vida dos pacientes que precisam delas. A Fortrea fornece gerenciamento de testes clínicos de fase I-IV, farmacologia clínica, soluções de testes com tecnologia diferenciada e serviços pós-aprovação. As soluções da Fortrea utilizam suas três décadas de experiência abrangendo mais de 20 áreas terapêuticas, sua dedicação ao rigor científico, insights excepcionais e uma forte rede de pesquisadores. Nossa equipe talentosa e diversificada de aproximadamente 19.000 pessoas que trabalham em mais de 90 países é dimensionada para fornecer soluções focadas e ágeis para clientes de todo o mundo. Saiba mais sobre como a Fortrea está se tornando uma força transformadora de pipeline para paciente na Fortrea.com e siga-nos no LinkedIn e X (antigo Twitter) @Fortrea.

Contatos da Fortrea:
Fortrea para Mídia: Galen Wilson – 703-298-0802, media@fortrea.com
Fortrea para Mídia: Kate Dillon – 646-818-9115, kdillon@prosek.com

GlobeNewswire Distribution ID 8994772

Fortrea Convenes New Site Advisory Board

Fortrea’s Site Advisory Board brings research leaders together to focus on evolving site, sponsor and patient relationships

DURHAM, N.C., Dec. 13, 2023 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced it convened last week the inaugural meeting of its Site Advisory Board, a collaboration between clinical research investigator sites (“sites”) and industry leaders to create a better clinical trial experience for sites, patients and clinical study sponsors (“sponsors”) by targeting changes in technology, operational planning and delivery, commercial terms and community engagement.

Fortrea places sites and investigators at the forefront of clinical trial planning, leveraging their perspectives to drive changes that will improve the speed of trial execution, ease study start up and increase recruitment efficiency. These changes address long-standing challenges within clinical trials and will result in a better site, patient and sponsor trial experience. The Site Advisory Board will be responsible for providing insight and feedback on strategies and solutions proposed regarding sites, patients, trial operations and relevant technology.

“Sites and investigators are critical to the industry at every stage of clinical development, and they traditionally have faced hard-to-solve challenges in clinical trials alone. We welcome their insights in protocol design and actively engage them in early conversations with our operational teams and sponsors to quickly establish the most efficient, patient-focused trial plans,” said Mike Clay, vice president, Development Strategy and Growth, at Fortrea. “The formation of the Site Advisory Board marks an acceleration of our site-focused strategy and includes representation from incredibly impressive leaders, creating a think tank for our industry. The Board will also serve as a cornerstone of our ability to respond to sponsors with insights that improve the predictability of their trials, working together to develop efficient operational plans and provide sponsors with a high degree of confidence in speed of patient recruitment and overall trial delivery.”

Inaugural members of Fortrea’s Site Advisory Board include leaders and experts from Circuit Clinical, Elligo Health Research, FutureMeds, Javara, MD Anderson Cancer Center Foundation Spain, ObjectiveHealth, Pratia S.A. and Velocity Clinical Research, representing 440 sites across more than 25 therapeutic areas and nine countries and providing access to diverse patient communities.

What Fortrea’s Site Advisory Board members are saying…

“We firmly believe that this collaborative approach, bringing together both CRO and sites, will enable all stakeholders to align more effectively on perspectives within the clinical trial market,” said Łukasz Bęczkowski, chief operating officer at Pratia. “This, undoubtedly, empowers us to act together in a more efficient manner. Initiatives like these play a crucial role in propelling us all towards positive and expedited changes.”

“Fortrea is taking a ‘listen first’ approach by giving sites an equal voice towards the most effective working practices for dynamic patient communities and site stakeholders, leading to the best service to clinical trial sponsors,” said Nick Spittal, chief operations officer at Velocity Clinical Research.

“Fortrea is leading the industry in making partnerships more productive and efficient, from trial process to business relationships, all in the effort to accelerate new products to market,” said Barry Simms, chief operating officer at Elligo Health Research.

“Providing the appropriate patient access solution is vital in determining the ultimate success of a clinical trial. Historically, care providers have not been involved in the early development of research planning and strategy,” said Colleen Hoke, chief executive officer at ObjectiveHealth. “We are very supportive of Fortrea employing an innovative new approach to engage with healthcare site partnership providers, who are key to delivering successful research results, early in the planning process.”

“FutureMeds is delighted to join the Fortrea Site Advisory Board to build better understanding between key stakeholders in the clinical research industry,” said Radek Janiak, chief executive officer at FutureMeds. “Hearing the voice of patients, investigators and sites will put Fortrea in a pole position for bringing new therapies to the market.”

“Working across the vast clinical trial ecosystem is complex and requires highly functional partnerships centered on trust and competence,” said Michelle Rule, senior vice president of enterprise optimization at Javara. “Fortrea’s genuine commitment to building a forum and working relationships through the Site Advisory Board exhibits dedication to progress for all stakeholders in research and, most of all, the patients.”

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology-enabled trial solutions and post-approval services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of about 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.

Fortrea Contacts:
Fortrea Media: Galen Wilson – 703-298-0802, [email protected]
Fortrea Media: Kate Dillon – 646-818-9115, [email protected]

GlobeNewswire Distribution ID 8994021

Global alternative assets remain resilient in 2023 amid economic uncertainty — Preqin Global Reports 2024

Pockets of opportunity emerge in private credit and secondaries

LONDON, Dec. 13, 2023 (GLOBE NEWSWIRE) — Today Preqin, the global leader in alternative assets data, tools, and insights, published its Alternatives in 2024 report, part of the Preqin Global Reports 2024. The report provides analysis on trends on key factors and trends driving the alternative assets industry.

While 2023 is a year so far characterized by market headwinds and a challenging fundraising environment for investors and fund managers alike, Preqin analysts remain optimistic about the outlook for global alternative assets. For instance, private debt fundraising fared relatively well in comparison to other private capital asset classes, while secondaries deal flow should start to pick up going into 2024 as the market comes back into balance.

Cameron Joyce, Head of Private Equity, Research Insights at Preqin, says, “Amid the formidable headwinds marked by swiftly tightening monetary policy and economic uncertainty, alternative assets have remained comparatively resilient. The industry continues to evolve rapidly, and promising opportunities are presenting themselves in areas such as private debt and secondaries. We continue to forecast solid growth for the industry despite softening expectations around fundraising and performance.”

Key highlights from each asset class:

Private equity faces a stern test:

The private equity market has been hampered by rising interest rates – which have weighed on deal activity – and a constrained exit environment. Dealmakers are hoping for an increase in activity during 2024 and long-term investor appetite remains strong.

Venture capital investor sentiment on performance improves:

Venture capital returns have been challenged by factors such as the poor exit environment, elevated asset valuations, and climbing interest rates. Noting this, our latest investor survey shows that investors’ outlook is shifting, and they are comparatively more positive on the performance of the asset class over the next 12 months.

Private debt fundraising holds up:

Private debt’s floating-rate structure and seniority in the capital stack are especially attractive for investors seeking more defensive assets in challenging conditions, with strategies such as mezzanine debt growing in popularity.

Hedge funds’ AUM rises despite net outflows:

Hedge funds’ AUM growth has been driven primarily by asset returns and not inflows and outflows. In fact, hedge fund returns during months of market volatility proved that they can be effective in providing investors with downside protection. Niche strategies such as cryptocurrencies and insurance-linked securities (ILS) gained prominence due to their low public market correlation.

Real estate under pressure:

Rising interest rates have weighed on investment sentiment, resulting in weaker fundraising and deal activity. As investors flock toward larger funds in search of a sense of security, fundraising has been even more challenging for first-time and smaller funds.

Infrastructure may be turning a corner:

Fundraising fell sharply in 2023, a significant reversal after fund managers amassed record sums in 2022. But third-quarter deal activity proved robust and tailwinds from energy transition will continue to underpin the long-term growth of unlisted infrastructure.

For more information, contact Mimi Celeste Taylor at [email protected].  

Notes to the editors

Alternatives in 2024 is a freely available version to accompany the Preqin Global Reports 2024. This complimentary report explores the impact of macroeconomic headwinds and market volatility on alternative assets this year and beyond.

If you are a full-time member of the press and would like to receive a full copy of any of the following reports, please get in touch: Private equity, venture capital, private debt, hedge funds, real estate and infrastructure. For non-press, the 2024 Preqin Global Reports are available for Preqin Insights+ subscribers.

About Preqin

Preqin, the Home of Alternatives™, empowers financial professionals who invest in or allocate to alternatives with essential data and insight to make confident decisions. It supports them throughout the entire investment lifecycle with critical information and leading analytics solutions. The company has pioneered rigorous methods of collecting private data for over 20 years, enabling more than 200,000 professionals globally to streamline how they raise capital, source deals and investments, understand performance, and stay informed. For more information visit www.preqin.com.

GlobeNewswire Distribution ID 1000903920